Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1933 1
1944 1
1947 3
1948 1
1951 2
1952 2
1953 3
1954 3
1955 8
1956 3
1957 9
1958 7
1959 8
1960 4
1961 7
1962 7
1963 19
1964 9
1965 7
1966 7
1967 7
1968 17
1969 17
1970 14
1971 17
1972 17
1973 21
1974 18
1975 18
1976 16
1977 21
1978 27
1979 23
1980 19
1981 27
1982 19
1983 18
1984 27
1985 15
1986 18
1987 20
1988 32
1989 32
1990 33
1991 28
1992 36
1993 40
1994 38
1995 32
1996 36
1997 38
1998 51
1999 46
2000 42
2001 34
2002 42
2003 32
2004 48
2005 54
2006 53
2007 56
2008 53
2009 66
2010 58
2011 62
2012 70
2013 66
2014 73
2015 66
2016 74
2017 59
2018 71
2019 71
2020 72
2021 71
2022 54
2023 29

Text availability

Article attribute

Article type

Publication date

Search Results

2,162 results

Results by year

Filters applied: . Clear all
Page 1
A no-brainer.
Butler RM, Gray WA. Butler RM, et al. Catheter Cardiovasc Interv. 2020 Nov;96(6):1304-1305. doi: 10.1002/ccd.29360. Catheter Cardiovasc Interv. 2020. PMID: 33217187
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH. Howell SJ, et al. Among authors: butler r. Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4. Lancet Oncol. 2022. PMID: 35671774 Free PMC article. Clinical Trial.
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.
Seligmann JF, Fisher DJ, Brown LC, Adams RA, Graham J, Quirke P, Richman SD, Butler R, Domingo E, Blake A, Yates E, Braun M, Collinson F, Jones R, Brown E, de Winton E, Humphrey TC, Parmar M, Kaplan R, Wilson RH, Seymour M, Maughan TS; FOCUS4 Trial Investigators. Seligmann JF, et al. Among authors: butler r. J Clin Oncol. 2021 Nov 20;39(33):3705-3715. doi: 10.1200/JCO.21.01435. Epub 2021 Sep 18. J Clin Oncol. 2021. PMID: 34538072 Free PMC article. Clinical Trial.
In reply.
Ledford CK, Butler RJ, Queen RM, Bolognesi MP. Ledford CK, et al. Among authors: butler rj. J Arthroplasty. 2015 May;30(5):896. doi: 10.1016/j.arth.2014.10.030. Epub 2014 Nov 5. J Arthroplasty. 2015. PMID: 25468781 No abstract available.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Among authors: butler r. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.
2,162 results